OBIO CAAP Company: ImmunoBiochem Corporation Enters Into Collaboration & Option Agreement with Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates.  The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs with superior properties, targeting triple-negative breast cancer. 

Evaluating APC’s technology to site-selectively modify our novel conjugates may help us create better drug candidates and generate a profound impact in the treatment of triple-negative breast cancer.
— Anton Neschadim, CEO, ImmunoBiochem Corporation